Novartis Inks $750M Flagship Pact for Cardio Innovation
Novartis makes a $750M flagship pact to address cardiovascular disease innovation.
Read MorePosted by Shajini | Jun 27, 2025 | Cardiometabolic, Dealstreet, News
Novartis makes a $750M flagship pact to address cardiovascular disease innovation.
Read MorePosted by Shajini | Jun 26, 2025 | News, Pricing & Market Access |
South Korea’s new pharma pricing reforms reward innovation and expand access for industry.
Read MorePosted by Shajini | Jun 26, 2025 | News, Regulatory |
FDA investigates Elevidys deaths, raising new safety and regulatory questions for gene therapies.
Read MorePosted by Shajini | Jun 26, 2025 | Dealstreet, News, Oncology
Gilead and Kymera seal a $750M deal for innovative CDK2 molecular glue degraders in oncology.
Read MorePosted by Shajini | Jun 26, 2025 | Neurology, News, Regulatory |
Neuron23 advances NEU-411 into Phase II Parkinson’s trial, driven by biomarker-based strategies and strong investor support.
Read More